Literature DB >> 24090321

Challenges in managing patients in Australia with chronic hepatitis B: the General Practitioners' perspective.

Jack Wallace1, Behzad Hajarizadeh, Jacqui Richmond, Stephen McNally.   

Abstract

OBJECTIVE: General Practitioners (GPs) are essential to reducing the impact of chronic hepatitis B (CHB) given their clinical management role where only 56% of people with the infection in Australia have been diagnosed. This qualitative study aimed to identify the challenges GPs face in effectively responding to CHB.
METHODS: Semi-structured interviews were conducted with 26 GPs self-identifying as having a 'high caseload' of patients and/or a particular interest in CHB. Participants were recruited from five jurisdictions and came from diverse ethnicities, clinical experience and practice profile. Interview data were analysed according to the principles of grounded theory.
RESULTS: Patient and GP knowledge, a lack of community awareness, and language and cultural diversity impeded the GP response to CHB. Communication with specialists was reported as challenging with unclear referral pathways, limited feedback from specialists after referral, and poor liaison and support for managing people living with CHB. Regulations restricting GPs capacity to respond included the lack of prescribing opportunities, fear of Medicare auditing for screening the populations most at risk, and inadequate financial support given the complexity of CHB and the communities most affected by the infection.
CONCLUSIONS: General Practitioners require additional skills and resources to support the effective management of people with CHB. These include improved awareness and knowledge about the infection, adequate financial resources to support patient management, and effective referral pathways and support.
© 2013 The Authors. ANZJPH © 2013 Public Health Association of Australia.

Entities:  

Keywords:  chronic hepatitis B; general practice; public policy

Mesh:

Year:  2013        PMID: 24090321     DOI: 10.1111/1753-6405.12127

Source DB:  PubMed          Journal:  Aust N Z J Public Health        ISSN: 1326-0200            Impact factor:   2.939


  7 in total

1.  A survey of knowledge, attitudes, barriers and support needs in providing hepatitis B care among GPs practising in Australia.

Authors:  Yinzong Xiao; Caroline van Gemert; Jess Howell; Jack Wallace; Jacqueline Richmond; Emily Adamson; Alexander Thompson; Margaret Hellard
Journal:  BMC Prim Care       Date:  2022-06-02

2.  Time for universal hepatitis B screening for Australian adults.

Authors:  Nicole L Allard; Jennifer H MacLachlan; Lien Tran; Nafisa Yussf; Benjamin C Cowie
Journal:  Med J Aust       Date:  2021-06-13       Impact factor: 12.776

Review 3.  The role of the general practitioner in the screening and clinical management of chronic viral hepatitis in six EU countries.

Authors:  A Bechini; M Levi; A Falla; A Ahmad; I Veldhuijzen; E Tiscione; P Bonanni
Journal:  J Prev Med Hyg       Date:  2016

4.  Development and Application of the Chinese (Mainland) Version of Chronic Liver Disease Questionnaire to Assess the Health-Related Quality of Life (HRQoL) in Patients with Chronic Hepatitis B.

Authors:  Yanli Liu; Sai Zhang; Yali Zhao; Juan Du; Guanghui Jin; Shuang Shao; Xiaoqin Lu
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240

5.  Hepatitis B-Related Concerns and Anxieties Among People With Chronic Hepatitis B in Australia.

Authors:  Behzad Hajarizadeh; Jacqui Richmond; Naomi Ngo; Jayne Lucke; Jack Wallace
Journal:  Hepat Mon       Date:  2016-05-21       Impact factor: 0.660

6.  The Role of Primary Health Care in Hepatitis B Testing and Management: A Case Study.

Authors:  Jacqueline A Richmond; Joe Sasadeusz; Meredith Temple-Smith
Journal:  J Community Health       Date:  2018-02

Review 7.  Progress and challenges in the comprehensive management of chronic viral hepatitis: Key ways to achieve the elimination.

Authors:  Fátima Higuera-de la Tijera; Alfredo Servín-Caamaño; Luis Servín-Abad
Journal:  World J Gastroenterol       Date:  2021-07-14       Impact factor: 5.742

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.